Emerging research suggests that GLP-1 medications may help reduce addictive behaviors, including alcohol cravings and cigarette smoking
A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
Regarding pain modulation, various studies have reported that GLP-1 analogs exert antinociceptive effects on the central nervous system
Furthermore, regarding the mechanisms of GLP-1 secretion regulation in intestinal L-cells, including the potentiation mechanism of the main pathway, many unresolved aspects remain to be elucidated
Starting Slowly Doctors typically prescribe low starting doses and gradually increase them
Final MRP: 3,200 - 3,800 per month
